Decentralized Clinical Trials: Key Considerations For Sites & PIs

Dr. David Morin

Article:
Decentralized Clinical Trials: Key Considerations For Sites & PIs

In this article, Dr. David Morin, HMG’s Director of Clinical Research and the 2022 chair of the Association of Clinical Research Professionals Board of Trustees, reflects on the responsibility principal investigators (PIs) have to safely supervise patient centric clinical trials and provide sponsors with valid and complete data to ensure the best care for patients.

He discusses the benefits of adapting decentralized clinical trials (DCTs) to broaden trial access and participation to increase diversity of study populations through a combination of on-site and off-site processes. He then breaks down the different regulatory processes and roles sponsors, study teams, investigators, and other stakeholders must consider for the successful implementation of DCTs. Learn more about these key considerations, click here for the article.